Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease

References

1. Bosch F. X., Lorincz A., Munoz N., Meijer C. J. L. M., Shah K. V. 2002; The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244–265 [CrossRef]
   [Google Scholar]
2. de Gruijl T. D., Bontkes H. J., Walboomers J. M. M., Coursaget P., Stukart M. J., Dupuy C., Kueter E., Verheijen R. H. M., Helmerhorst T. J. M. other authors 1999; Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. J Gen Virol 80:399–408
   [Google Scholar]
3. Gross G., Pfister H. 2004; Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol 193:35–44 [CrossRef]
   [Google Scholar]
4. Harper D. M., Franco E. L., Wheeler C. M., Moscicki A. B., Romonowski B., Roteli-Martins C. M., Jenkins D., Schuind A., Clemens S. A. C. other authors 2006; Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247–1255 [CrossRef]
   [Google Scholar]
5. Kawana K., Yasugi T., Kanda T., Kawana Y., Hirai Y., Yoshikawa H., Taketani Y. 2002; Neutralizing antibodies against oncogenic human papillomavirus as a possible determinant of the fate of low-grade cervical intraepithelial neoplasia. Biochem Biophys Res Commun 296:102–105 [CrossRef]
   [Google Scholar]
6. Lowy D. R., Schiller J. T. 2006; Prophylactic human papillomavirus vaccines. J Clin Invest 116:1167–1173 [CrossRef]
   [Google Scholar]
7. Marais D., Rose R. C., Williamson A. L. 1997; Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa. J Med Virol 51:126–131 [CrossRef]
   [Google Scholar]
8. Marais D. J., Best J. M., Rose R. C., Keating P., Soeters R., Denny L., Dehaeck C. M. C., Nevin J., Kay P. other authors 2001; Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia 1. J Med Virol 65:149–154 [CrossRef]
   [Google Scholar]
9. Marais D. J., Sampson C., Jeftha A., Dhaya D., Passmore J.-A. S., Denny L., Rybicki E. P., Van Der Walt E., Stephen L. X. G., Williamson A.-L. 2006; More men than women make mucosal IgA antibodies to human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population. BMC Infect Dis 6:1471
   [Google Scholar]
10. Mqoqi N., Kellet P., Sitas F., Musa J. 2004 Incidence of Histologically Diagnosed Cancer in South Africa, 1998–1999 Johannesburg: National Cancer Registry of South Africa;
    [Google Scholar]
11. Pagliusi S. R., Dillner J., Pawlita M., Quint W. G. V., Wheeler C. M., Ferguson M. 2006; Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays – an update. Vaccine 24:S193–200 [CrossRef]
    [Google Scholar]
12. Pastrana D. V., Buck C. B., Pang Y. Y. S., Thompson C. D., Castle P. E., FitzGerald P. C., Kjaer S. K., Lowy D. R., Schiller J. T. 2004; Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205–216 [CrossRef]
    [Google Scholar]
13. Rudin A., Johansson E. L., Bergquist C., Holmgren J. 1998; Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun 66:3390–3396
    [Google Scholar]
14. Sonnex C. 1998; Influence of ovarian hormones on urogenital infection. Sex Transm Infect 74:11–19 [CrossRef]
    [Google Scholar]
15. Viscidi R. P., Ahdieh-Grant L., Clayman B., Fox K., Massad L. S., Cu-Uvin S., Shah K. V., Anastos K. M., Squires K. E. other authors 2003; Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis 187:194–205 [CrossRef]
    [Google Scholar]
16. Viscidi R. P., Snyder B., Cu-Uvin S., Hogan J. W., Clayman B., Klein R. S., Sobel J., Shah K. V. 2005; Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 14:283–288
    [Google Scholar]
17. Walboomers J. M. M., Jacobs M. V., Manos M. M., Bosch F. X., Kummer J. A., Shah K. V., Snijders P. J. F., Peto J., Meijer C. J. L. M., Munoz N. 1999; Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19 [CrossRef]
    [Google Scholar]
18. White W. I., Wilson S. D., Bonnez W., Rose R. C., Koenig S., Suzich J. A. 1998; In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 72:959–964
    [Google Scholar]